VPC
IBIO icon

Vestal Point Capital’s iBio IBIO Stock Holding History

Vestal Point Capital’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.55M Buy
+2,600,000
New +$4.65M 0.11% 62

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vestal Point Capital's IBIO Position: Q2 2026 in Review

Vestal Point Capital opened a new position in iBio (IBIO) in Q2 2026: 2,600,000 shares worth $4.55M. The stake represents 0.11% of the portfolio and ranks #62 among its holdings.

56 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Vestal Point Capital held 2,600,000 shares of iBio worth $4.55M as of Q2 2026.
  • iBio was a new Vestal Point Capital position in Q2 2026.
  • iBio made up 0.11% of Vestal Point Capital's portfolio in Q2 2026, its #62 holding.
  • 56 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.